Pure Global
NCT04548284

Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO

Periorbitally Injected Glucocorticoids for Mild TAO: A Randomized Controlled Study
Sun Yat-sen University·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Thyroid Associated Ophthalmopathy
Drug/Device/Intervention
Glucocorticoids
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sun Yat-sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 3
Start date
May 01, 2021
End date
Dec 01, 2023
Enrollment
142 participants
Primary outcome

Change of Clinical Activity Score (CAS) score,Change of NOSPECS score

Summary

The purpose of this study is to determine whether periorbital injection of glucocorticoid is
 effective and necessary in the treatment of mild TAO.

ICD-10 classifications
ThyroiditisDisorders of thyroid glandThyroiditis, unspecifiedOther disorders of thyroidDisorder of thyroid, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04548284
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04548284 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sun Yat-sen University and is currently Recruiting. The study focuses on Thyroid Associated Ophthalmopathy. Target enrollment is 142 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.